Valuation: Alzamend Neuro, Inc.

Market Cap 8.83M 7.75M 7.32M 6.67M 12.49M 846M 12.57M 87.58M 33.92M 432M 33.16M 32.44M 1.39B P/E 2027 *
-1.74x
P/E 2028 * -2.1x
Enterprise Value 8.83M 7.75M 7.32M 6.67M 12.49M 846M 12.57M 87.58M 33.92M 432M 33.16M 32.44M 1.39B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
97.34%
Yield 2027 *
-
Yield 2028 * -
1 day+0.55%
1 week-3.17%
Current month+14.38%
1 month+9.91%
3 months+52.50%
6 months+74.29%
Current year+0.55%
1 week 1.76
Extreme 1.7635
1.95
1 month 1.51
Extreme 1.51
1.95
Current year 0.84
Extreme 0.84
2.54
1 year 0.84
Extreme 0.84
2.68
3 years 0.84
Extreme 0.84
350.73
5 years 0.84
Extreme 0.84
4,819.5
10 years 0.84
Extreme 0.84
45,292.48
Manager TitleAgeSince
Chief Executive Officer 50 2018-11-19
Director of Finance/CFO 64 2022-08-04
General Counsel 57 2019-04-30
Director TitleAgeSince
Chairman 56 2016-02-25
Chairman 57 2021-05-31
Director/Board Member 50 2020-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Sell

Founder

-2,000 0.0417%
8/26/26 OtherCompany 0 0% -
7/31/26 FreeCompany 7,500 0.1565%
Change 5-day change 1-year change 3-year change Capi.($)
+0.55%-3.17%-24.07%-99.42% 8.83M
-0.14%+4.33%+9.00%+34.85% 47.97B
-1.69%+1.48%+50.57%+33.71% 44.5B
+2.56%+7.34%+366.69%+609.24% 43.93B
+0.24%+2.85%+10.67%+87.77% 41.03B
-0.62%-1.11%+4.65%+46.13% 29.85B
-0.28%+1.07%+24.58%+149.55% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+43.26% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.13%+1.80%+53.03%+113.13% 27B
Weighted average by Cap. +0.11%+2.86%+79.67%+159.08%

Financials

2027 *2028 *
Net sales - -
Net income -10.8M -9.48M -8.95M -8.16M -15.27M -1.04B -15.38M -107M -41.48M -529M -40.55M -39.67M -1.7B -10.8M -9.48M -8.95M -8.16M -15.27M -1.04B -15.38M -107M -41.48M -529M -40.55M -39.67M -1.7B
Net Debt - -
Logo Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Employees
5
Date Price Change Volume
26-09-25 US$1.830 +0.55% 23,319
26-09-24 US$1.820 -6.19% 150,562
26-09-23 US$1.940 0.00% 45,866
26-09-22 US$1.940 0.00% 91,217
26-09-21 US$1.940 +2.65% 206,807
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.830USD
Average target price
26.00USD
Spread / Average Target
+1,320.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALZN Stock